Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icotinib - Zhejiang Betta Pharma

Drug Profile

Icotinib - Zhejiang Betta Pharma

Alternative Names: BPI-2009; BPI-2009C; BPI-2009H; Conmana; Icotinib hydrochloride

Latest Information Update: 19 Jul 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beta Pharma
  • Developer Beta Pharma; Zhejiang Betta Pharma
  • Class 3-ring heterocyclic compounds; Alkynes; Antineoplastics; Crown ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Brain metastases; Lung cancer; Nasopharyngeal cancer; Oesophageal cancer; Psoriasis
  • No development reported Pancreatic cancer

Most Recent Events

  • 27 Nov 2018 Betta Pharmaceuticals plans a phase II trial for Non-Small Cell Lung Cancer with brain metastases in December 2018 (NCT03754530)
  • 21 Nov 2018 Betta Pharmaceuticals initiates enrolment in a phase II trial for Non-small cell lung cancer (Neoadjuvant Therapy; Late-stage disease) in China (NCT03749213)
  • 14 Nov 2018 Betta Pharmaceuticals terminates a phase II trial in Psoriasis in China, as it failed to meet the primary efficacy endpoint (NCT03222622)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top